Abiomed Inc. (NASDAQ: ABMD), a leading provider of heart recovery products designed to recover hearts and eliminate in-hospital deaths from heart attacks and high risk percutaneous coronary interventions (PCI), today announced its schedule of events at the American College of Cardiology (ACC) 58th Annual 2009 Scientific Session, being held March 29 - 31, at the Orlando Convention Center in Orlando, Florida. The ACC conference features the latest and most innovative findings in cardiovascular science, as well as the most clinically relevant practical applications. Abiomed will exhibit its comprehensive portfolio of heart recovery products spanning the continuum of cardiovascular patient care from the catheterization lab (cath lab) to the surgery suite.
The Abiomed ACC booth (#2653), will include daily demonstrations and hands-on simulation of its extensive heart recovery product suite, including: Impella 2.5; Impella 5.0; AB5000™ portable driver; and AB5000TMCirculatory Support System.
The Impella 2.5 will be featured in five live cases at the ACC conference, including Columbia University Medical Center, Cedars-Sinai Medical Center, Saint Luke’s Hospital and Mid-America Heart Institute, and St. Vincent Hospital and the Heart Center of Indiana. Impella 2.5 will also be featured in a presentation made by physicians from Washington Hospital Center in Washington, DC.
Schedule of Abiomed Events at ACC 2009
Impella live cases and presentations at ACC will take place during following dates and times:
Saturday, March 28
Live Cases
10 a.m. to 12 p.m. ET
- Jeffrey W. Moses, M.D., Director of the Center for Interventional Vascular Therapy, New York-Presbyterian Hospital / Columbia University Medical Center
- Raj Makkar, M.D., Director, Interventional Cardiology and Cardiac Catheterization Laboratory, Cedars-Sinai Medical Center – 10 a.m. ET
- Raj Makkar, M.D., Director, Interventional Cardiology and Cardiac Catheterization Laboratory, Cedars-Sinai Medical Center – 11 a.m. ET
Sunday, March 29
Live Case
10 a.m. to 12 p.m. ET
- Barry Rutherford, M.D., Director of Interventional Research, Saint Luke's Mid America Heart Institute
Presentation
2:48 to 3 p.m. ET
- “Will the Net Clinical Benefit of the Prophylactic Use of the Impella LP 2.5 Device Demonstrate Superiority Over the Intra-Aortic Balloon Pump for High-Risk Percutaneous Coronary Intervention?” Washington Hospital Center, Washington, DC.
Monday, March 30
Live case
11 a.m. ET
- James B. Hermiller Jr, M.D., St. Vincent Hospital/The Heart Center of Indiana
ABOUT IMPELLA
The Impella 2.5 is the world’s smallest heart pump and is inserted percutaneously in the cath lab via the femoral artery into the left ventricle. Up to 2.5 liters of blood per minute is delivered by the pump from the left ventricle into the ascending aorta, providing the heart with active support in critical situations. Now approved in more than 40 countries, Impella 2.5 has been used to treat over 1,700 patients worldwide and has been the subject of more than 50 peer-reviewed publications.
ABOUT ABIOMED
Based in Danvers, Massachusetts, Abiomed, Inc., is a leading provider of medical devices that provide circulatory support to acute heart failure patients across the continuum of care in heart recovery. Our products are designed to enable the heart to rest, heal and recover by improving blood flow and/or performing the pumping of the heart. For additional information please visit: www.abiomed.com.
FORWARD-LOOKING STATEMENTS
This Release contains forward-looking statements, including statements regarding development of Abiomed's existing and new products, the Company's progress toward commercial growth, and future opportunities and expected regulatory approvals. The Company's actual results may differ materially from those anticipated in these forward-looking statements based upon a number of factors, including uncertainties associated with development, testing and related regulatory approvals, including anticipated future losses, complex manufacturing, high quality requirements, dependence on limited sources of supply, competition, technological change, government regulation, future capital needs and uncertainty of additional financing, and other risks and challenges detailed in the Company's filings with the Securities and Exchange Commission, including the Annual Report filed on Form 10-K and most recently filed Quarterly Report on Form 10-Q. Readers are cautioned not to place undue reliance on any forward-looking statements, which speak only as of the date of this Release. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances that occur after the date of this Release or to reflect the occurrence of unanticipated events.
Abiomed, Impella, iPulse, BVS5000, AB5000 and the Abiomed logo are all trademarks of Abiomed. Other company and product names may be trademarks of their respective owners.
Abiomed, Inc.
Aimee Maillett, 978-646-1553
Public Relations
Specialist
ir@abiomed.com